Lisata Therapeutics (LSTA) investor relations material

Executive summary

• Clinical-stage pharmaceutical company focused on therapies for solid tumors, with certepetide as lead investigational product targeting tumor penetration and microenvironment modification.

• Terminated merger agreement with Kuva Labs in July 2026 after Kuva failed to secure financing; commenced litigation to recover a $2M termination fee and damages.

• Board is actively reviewing strategic alternatives, including potential acquisition, merger, asset sale, or liquidation.

• Implemented a 72% workforce reduction in August 2026 to reduce costs and preserve cash while exploring options.

Financial highlights

• Cash and cash equivalents were $10.4M as of June 30, 2026, down from $16.0M at year-end 2025.

• Net loss for Q2 2026 was $2.9M, an improvement from $4.7M in Q2 2025; six-month net loss was $7.4M, improved from $9.4M year-over-year.

• Operating expenses for Q2 2026 were $4.0M, down 19% year-over-year, driven by lower R&D costs.

• No revenue recognized in Q2 or first half of 2026; prior year included $70K from a license agreement.

• Other income in Q2 2026 was $1.1M, mainly from a $1M payment related to the terminated Kuva merger.

Outlook and guidance

• Management expresses substantial doubt about the ability to continue as a going concern for the next 12 months without additional funding.

• Ongoing efforts to secure new funding and strategic transactions; failure to do so may result in liquidation or wind-down.

• Short-term liquidity needs expected to be met with existing cash, but additional capital is required for ongoing operations.